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Arsenic (As) is a naturally occurring toxic
metalloid and a potent human carcinogen
[International Agency for Research on Cancer
(IARC) 1987]. The cancer-promoting effects
of environmental exposures to inorganic
arsenic (iAs) have been examined by epidemi-
ologic studies and in laboratory experiments.
Much less attention has been paid to the
adverse effects of iAs that do not involve
malignancies. Epidemiologic evidence suggests
that type 2 (noninsulin dependent) diabetes
mellitus may be one of the most common
noncancerous diseases associated with chronic
exposures to iAs. Increased prevalences of
type 2 diabetes or symptoms consistent with
this disease have been associated with the con-
sumption of drinking water containing high
levels of iAs (Chen et al. 1995; Lai et al. 1994;
Rahman et al. 1998, 1999; Tseng et al. 2000,
2002; Wang et al. 2003) or with chronic
exposures to iAs in occupational settings
(Jensen and Hansen 1998; Rahman and
Axelson 1995; Rahman et al. 1996). Although
not all epidemiologic studies support the asso-
ciation between iAs exposure and diabetes
(Navas-Acien et al. 2006), the existing evi-
dence provides sufﬁcient basis for investigation
of the diabetogenic effects of iAs.
Type 2 diabetes is characterized by dis-
ruptions in whole-body glucose homeostasis
due to insulin resistance and impaired glucose
utilization by peripheral tissues, including
skeletal muscle and adipose tissue. The
insulin-dependent activation of glucose
uptake in these tissues is one of the key mech-
anisms that regulates glucose homeostasis.
The insulin-activated signal transduction
mechanism that stimulates glucose uptake by
adipocytes has been extensively studied. It
includes the autophosphorylation of the
β-subunit of the insulin receptor (IRβ) upon
binding of insulin to the α-subunit of the
receptor (IRα), the subsequent tyrosine phos-
phorylation of insulin receptor substrate 1 or
2 (IRS-1 or -2), and the binding of a phos-
phorylated IRS (p-IRS) to the regulatory
(p85) subunit of the class IA phosphatidyli-
nositol 3-kinase (PI-3K) that leads to the acti-
vation of its catalytic (p110) subunit. The
activated PI-3K catalyzes the phosphorylation
of phosphatidylinositol-4,5-bisphosphate
(PIP2) at the plasma membrane to phos-
phatidylinositol-3,4,5-triphosphate (PIP3)
(Farese 2001; Ruderman et al. 1990; White
and Kahan 1994). PIP3 facilitates 3-phospho-
inositide-dependent kinase-1/2 (PDK-1/2)
dependent phosphorylation/activation of pro-
tein kinase B (PKB/Akt) and two atypical
enzymes of the protein kinase C (PKC) fam-
ily, PKCλ and ζ (Chou et al. 1998; Le Good
et al. 1998; Standaert et al. 1997). The phos-
phorylation of PKB/Akt results in the translo-
cation of intracellular vesicles containing
glucose transporter-4 (GLUT4) from the per-
inuclear region to the plasma membrane and
in the stimulation of glucose uptake (Kohn
et al. 1996a; Tanti et al. 1997). In addition to
phosphorylated PKB/Akt (p-PKB/Akt), phos-
phorylated PKCλ (p-PKCλ), and PKCζ
(p-PKCζ) are thought to participate in the
stimulation of GLUT4 translocation in
response to insulin signaling (Elmendorf and
Pessin 1999; Ruderman et al. 1990). The
mechanism by which p-PKB/Akt, p-PKCλ
and ζ induce the translocation and fusion of
GLUT4-containing vesicles with the plasma
membrane, as well as the degree to which
each of these kinases participates in this event,
are unclear. Recent studies have indicated
that the PI-3K-dependent rearrangement of
actin ﬁlaments (Patel et al. 2003) and activa-
tion of the microtubule-associated motor pro-
tein kinesin (Imamura et al. 2003) contribute
to the translocation of GLUT4 to the plasma
membrane. The disruption of cytoskeletal
components may represent a potential mech-
anism by which As exposure inhibits insulin-
stimulated glucose uptake (ISGU). Notably,
As has been shown to bind to actin and tubu-
lin in human lymphoblastoid cells (Menzel
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BACKGROUND: Increased prevalences of diabetes mellitus have been reported among individuals
chronically exposed to inorganic arsenic (iAs). However, the mechanisms underlying the diabeto-
genic effects of iAs have not been characterized. We have previously shown that trivalent metabolites
of iAs, arsenite (iAsIII) and methylarsonous acid (MAsIII) inhibit insulin-stimulated glucose uptake
(ISGU) in 3T3-L1 adipocytes by suppressing the insulin-dependent phosphorylation of protein
kinase B (PKB/Akt). 
OBJECTIVES: Our goal was to identify the molecular mechanisms responsible for the suppression of
PKB/Akt phosphorylation by iAsIII and MAsIII.
METHODS: The effects of iAsIII and MAsIII on components of the insulin-activated signal transduc-
tion pathway that regulate PKB/Akt phosphorylation were examined in 3T3-L1 adipocytes. 
RESULTS: Subtoxic concentrations of iAsIII or MAsIII had little or no effect on the activity of phos-
phatidylinositol 3-kinase (PI-3K), which synthesizes phosphatidylinositol-3,4,5-triphosphate
(PIP3), or on phosphorylation of PTEN (phosphatase and tensin homolog deleted on chromosome
ten), a PIP3 phosphatase. Neither iAsIII nor MAsIII interfered with the phosphorylation of 3-phos-
phoinositide-dependent kinase-1 (PDK-1) located downstream from PI-3K. However, PDK-1
activity was inhibited by both iAsIII and MAsIII. Consistent with these ﬁndings, PDK-1-catalyzed
phosphorylation of PKB/Akt(Thr308) and PKB/Akt activity were suppressed in exposed cells. In
addition, PKB/Akt(Ser473) phosphorylation, which is catalyzed by a putative PDK-2, was also sup-
pressed. Notably, expression of constitutively active PKB/Akt restored the normal ISGU pattern in
adipocytes treated with either iAsIII or MAsIII. 
CONCLUSIONS: These results suggest that inhibition of the PDK-1/PKB/Akt-mediated transduction
step is the key mechanism for the inhibition of ISGU in adipocytes exposed to iAsIII or MAsIII, and
possibly for impaired glucose tolerance associated with human exposures to iAs. 
KEY WORDS: arsenic, diabetes, glucose uptake, PDK-1, PKB/Akt. Environ Health Perspect
115:734–742 (2007). doi:10.1289/ehp.9867 available via http://dx.doi.org/ [Online 29 January 2007]et al. 1999) and to inhibit the cytoskeletal
protein synthesis in Swiss 3T3 mouse cells (Li
and Chou 1992). 
The mechanisms by which exposure to iAs
may induce impaired glucose tolerance have
not been systematically studied. Data on the
effects of As on glucose homeostasis have been
generated almost exclusively in studies that
examined the metabolism of nutrients under
severe stress induced by chemical or physical
stimuli. Results of in vitro studies have consis-
tently shown significant increases in basal
(insulin-independent) glucose uptake by vari-
ous types of cells or dissected tissues exposed to
cytotoxic concentrations of a trivalent iAs,
arsenite (iAsIII), or an aromatic derivative of
AsIII, phenylarsine oxide (PAO) (Bazuine et al.
2003, 2004; Brazy et al. 1980; McDowell et al.
1997; Pasternak et al. 1991; Short 1965;
Sviderskaya et al. 1996; Widnell et al. 1990).
Consistent with these findings, some in vivo
studies have reported moderate or severe hypo-
glycemia in animals chronically exposed to
toxic, often lethal, concentrations of iAsIII or
arsenate (iAsV), in drinking water (Hughes and
Thompson 1996; Pal and Chatterjee 2004a,
2004b, 2005). Only limited information is
available on the effects of arsenicals on glucose
metabolism at low concentrations that are
compatible with environmental or occupa-
tional exposures. Micromolar concentrations of
PAO have been shown to inhibit basal or
ISGU by cultured cells (Liebl et al. 1992,
1995) and by intact skeletal muscle (Henriksen
and Holloszy 1990; Sowell et al. 1988). PAO
did not interfere with the insulin-dependent
phosphorylation of IRβ and did not interact
directly with glucose transporters (Frost and
Lane 1985; Frost et al. 1987). The effects of
physiologically relevant arsenicals on insulin-
stimulated glucose metabolism have only
recently been examined in this laboratory
(Walton et al. 2004). We have shown that
iAsIII and the products of iAs methylation in
humans, methylarsonous acid (MAsIII), and
dimethylarsinous acid (DMAsIII) (Thomas
et al. 2001), inhibit ISGU by 3T3-L1
adipocytes at concentrations that do not affect
cell viability. Exposures to these arsenicals did
not prevent IRβ and IRS phosphorylation or
formation of the PI-3K–p-IRS complex.
However, both iAsIII and MAsIII inhibited the
insulin-dependent phosphorylation of PKB/
Akt that mediates ISGU in adipocytes. In con-
trast, DMAsIII did not inhibit PKB/Akt phos-
phorylation, suggesting that this metabolite of
iAs inhibits ISGU by a PKB/Akt-independent
mechanism.
In the present study we examined the
molecular mechanisms of ISGU inhibition by
iAsIII and MAsIII, focusing mainly on the
components of the insulin-activated signal
transduction pathway that regulate PKB/Akt
phosphorylation in adipocytes. Results of this
work show that iAsIII and MAsIII inhibit
PDK-1 activity, thus suppressing PDK-1–
catalyzed phosphorylation of PKB/Akt and
p-PKB/Akt–mediated translocation of
GLUT4 transporters to the plasma mem-
brane. Notably, MAsIII was an order of mag-
nitude more potent than iAsIII as an inhibitor
of the PDK-1/PKB/Akt signal transduction
step and of glucose uptake in insulin-stimu-
lated adipocytes. Thus, the formation of
MAsIII in the methylation pathway for iAs
may play a critical role in determining the
extent of the diabetogenic effects associated
with chronic exposures to iAs. 
Materials and Methods
Cell culture and treatment. We obtained
3T3-L1 preadipocytes from Y. Patel (University
of North Carolina, Greensboro, North
Carolina). Myr-PKB/Akt–3T3-L1 preadipo-
cytes expressing constitutively active PKB/Akt
lacking the pleckstrin homology (PH) domain
were provided by S. Summers (University of
Colorado at Boulder, Boulder, Colorado).
Addition of the src myristoylation sequence
promotes constitutive membrane association
and activation of PKB/Akt (Kohn et al. 1996a,
1996b). A2myr-PKB/Akt–3T3-L1 adipocytes,
which express PKB/Akt containing a nonfunc-
tional src myristoylation domain, and 3T3-L1
adipocytes containing the empty expression
vector were also provided by S. Summers. All
cell lines were cultured in Dulbecco’s modiﬁed
Eagle medium (Gibco, Grand Island, NY) with
high glucose, 10% fetal bovine serum
(HyClone, Logan, UT), penicillin, and strepto-
mycin (Sigma Chemical Co., St. Louis, MO).
Cells were cultured at 37°C in a humidified
incubator in a 90% air and 10% CO2 atmos-
phere. To induce differentiation, postconﬂuent
cells were treated with a mixture of 0.5 mM
3-isobutyl-1-methylxanthine, 1 µM dexametha-
sone, and 1 µg/mL insulin (all from Sigma
Chemical Co.) for 48 hr and cultured in
insulin-containing medium for an additional
48 hr (Paul et al. 2003). All experiments were
performed between days 9 and 12 postinduc-
tion, when more than 90% of cells were fully
differentiated. Differentiated adipocytes were
treated with iAsIII (sodium salt, Sigma
Chemical Co.) or methylarsine oxide (provided
by W. Cullen, University of British Columbia,
Vancouver, Canada). Identity and purity of
methylarsine oxide was conﬁrmed by 1H-NMR
and mass spectrometry. In aqueous solutions,
methylarsine oxide is hydrolyzed to form
MAsIII (Petrick et al. 2001). Fresh stock solu-
tions of iAsIII and MAsIII in sterile phosphate-
buffered saline (PBS) were prepared before each
experiment to minimize the oxidation of iAsIII
to iAsV or MAsIII to methylarsonic acid
(MAsV). Adipocytes were incubated with
arsenicals or vehicle in a cell culture incubator
for 4 hr. 
Glucose uptake assay. The glucose uptake
assay followed the previously described pro-
cedures (Paul et al. 2003). Brieﬂy, adipocytes
were serum starved in the presence or absence
of arsenicals for 4 hr, washed with Krebs-
Ringer phosphate (KRP) buffer, and treated
with 1 µM insulin at 37°C for 10 min.
Insulin-activated cells were incubated for
10 min with 200 µM 2-[1-14C]-deoxy-
D-glucose (0.1 µCi/well) (NEN Life Science
Products, Inc., Boston, MA). To measure
basal (insulin-independent) glucose uptake, we
incubated cells with radiolabeled glucose with-
out pretreatment with insulin. After the incu-
bation, cells were washed twice with PBS
(0°C), and lysed in a solution of 0.5 N NaOH
and 10% SDS. Radioactivity in cell lysates was
measured, using a Wallac 1409 liquid scintil-
lation counter (Wallac, Turku, Finland). 
Evaluation of cytotoxic and apoptotic
effects of arsenicals. To determine cell viabil-
ity, we used the MTT assay, which measures
the conversion of 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT)
to purple formazan by mitochondrial dehy-
drogenases of viable cells (Carmichael et al.
1987), as previously described (Walton et al.
2004). Caspase-3 activity was examined in an
assay mixture containing cell lysate and
aminomethylcoumarin (AMC)-derived sub-
strate, Z-DEVD-AMC (Molecular Probes,
Carlsbad, CA). Cleavage of Z-DEVD-AMC
by caspase-3 yields a blue-ﬂuorescent product
(excitation/emission wavelength = 342/
441 nm) that was quantiﬁed by an HTS 7000
Bio Assay Reader (Perkin-Elmer, Norwalk,
CT). We examined DNA fragmentation in
adipocytes using TUNEL (terminal deoxynu-
cleotidyltransferase-mediated nick end label-
ing). For this assay, adipocytes were cultured
on glass coverslips coated with poly-L-lysine
(Sigma Chemical Co.) and treated with arseni-
cals. Cells were then fixed in 4% buffered-
paraformaldehyde and permeabilized in a
solution of 0.1% Triton X-100 and 0.1%
sodium citrate (Sigma Chemical Co.). DNA
strand breaks were enzymatically labeled on
3´-OH termini with fluorescein-linked
nucleotides, using the In Situ Cell Death
Detection Kit (Roche Applied Science,
Indianapolis, IN). Nuclei of both normal and
apoptotic cells were stained with 100 nM 4´,6-
diamidino-2-phenylindole dihydrochloride
(DAPI) (Sigma Chemical Co.). Labeled cells
were visualized using a Nikon Microphot FXA
ﬂuorescent microscope (Nikon, Tokyo, Japan).
Immunofluorescent analysis of GLUT4.
Adipocyte cultures on glass cover slips were
treated with arsenicals, activated with insulin,
and incubated with D-glucose (Sigma Chemical
Co.). After fixation with 4% buffered-
paraformaldehyde, adipocytes were rinsed with
ice-cold PBS and incubated with poly-L-lysine
(0.5 mg/mL) for 1 min. Cells were then treated
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7.5), 2 mM MgCl2, 23 mM KCl, 1 mM
EDTA] and pulse sonicated for 5 sec in a soni-
cation buffer [30 mM HEPES (pH 7.5), 6 mM
MgCl2, 70 mM KCl, 3 mM EGTA, 1 mM
dithiothreitol, 0.1 mM phenylmethylsulfonyl
fluoride (PMSF)], using a Fisher Model 100
Sonic Dismembrator equipped with a 12.7 ×
1.3  × 0.3-cm probe (Fisher Scientific,
Hampton, NH). Plasma membrane sheets
attached to the coverslip were washed twice
with the sonication buffer, incubated with an
anti-GLUT4 antibody (Santa Cruz Biotech,
Santa Cruz, CA) and labeled with Alexa-
fluor 594 (Molecular Probes). Fluorescent
images were captured, using a Zeiss LSM 110
ﬂuorescent microscope (Zeiss, Jena, Germany). 
Speciation analysis of As. We analyzed
arsenicals in cell cultures exposed to iAsIII or
MAsIII using hydride generation atomic
absorption spectrometry (HG-AAS) as previ-
ously described (Devesa et al. 2004). Cells and
culture medium were analyzed separately for
each treatment. Arsines were generated at
pH 1, cold-trapped, separated by their boiling
points, and analyzed, using a Perkin-Elmer
model 5100 PC atomic absorption spectrome-
ter (Perkin-Elmer). Under these conditions,
arsines were generated from both AsIII and
AsV species. Thus, total iAs (iAs = iAsIII +
iAsV), total methylarsenic (MAs = MAsIII +
MAsV), and total dimethylarsenic (DMAs =
DMAsIII + DMAsV) species were determined.
We confirmed the identities of arsenicals in
spectral peaks using aliquots of samples spiked
with standards. Calibration curves for each of
the arsenicals (0.5, 2.5, 10, 20, 80 ng As) were
generated to quantify results of the analyses.
Immunoblot analyses. Protein extracts were
prepared from cells treated with arsenicals,
activated with insulin, and incubated with
D-glucose, using a 25-mM HEPES (pH 7.4)
lysis buffer containing 1% NP 40, 100 mM
NaCl, 2% glycerol, 5 mM sodium fluoride,
1 mM EDTA, 1 mM sodium orthovanadate
(Na3VO4), 1 mM sodium pyrophosphate,
1 mM PMSF, 40 µg/mL aprotinin, 20 µg/mL
leupeptin, and 20 µg/mL pepstatin (all from
Sigma Chemical Co.). Protein extracts were
separated by 10% SDS-PAGE, electroblotted
to Immobilon-P membranes (Millipore,
Burlington, MA), and probed using the fol-
lowing antibodies: anti-p38 MAPK (mitogen-
activated protein kinase), anti-p-p38 MAPK,
anti-PKB/Akt, anti-p-PKB/Akt(Ser473) and
anti-p-PKB/ Akt(Thr308), anti-PTEN (phos-
phatase and tensin homolog deleted on
chromosome ten), anti-p-PTEN(Ser380), anti-
p-PDK-1(Ser241) (Cell Signaling Technology,
Beverly, MA); anti-PI-3K(p85) (Upstate
Biotechnology, Lake Placid, NY); and anti-
β-actin (Abcam, Cambridge, MA). The anti-
gen-antibody complexes on immunoblots were
treated with horseradish peroxidase–conju-
gated secondary antibodies (Santa Cruz
Biotechnology) and visualized using autoradi-
ography or the Gene Gnome imaging system
(Syngene, Frederick, MD).
Protein kinase activity assays. We meas-
ured PI-3K, PKB/Akt, and PDK-1 activities
in cell lysates from adipocytes treated with
arsenicals and activated with insulin after
immunoprecipitation with speciﬁc antibodies
bound to protein G agarose beads (Santa
Cruz Biotechnology). For a single assay we
used the immunoprecipitate from cells
cultured in one 10-cm plate. The assay condi-
tions were as follows:
PI-3K assay. PI-3K was immunoprecipi-
tated from control (untreated) adipocytes or
from adipocytes exposed to arsenicals with an
anti-phosphotyrosine (PY20) antibody. PI-3K
immunoprecipitated from insulin-activated
adipocytes pretreated with 1 nM wortmannin
(a specific inhibitor of PI-3K) was used as a
negative control. The enzyme activity was mea-
sured in a 50-µL assay mixture containing the
immunoprecipitated PI-3K, 20 mM HEPES
(pH 7.4), 50 mM MgCl2, 200 µM adenosine,
40 µM adenosine 5´-triphosphate (ATP) 
(all from Sigma Chemical Co.), 20 µCi
[γ-32P]-ATP (NEN Life Science Products, Inc.),
and L-α-phosphatidylinositol (PI) (Avanti
Polar Lipids Inc., Alabaster, AL) as a substrate
(Augustine et al. 1991). The reaction was
stopped by 1 N HCl. A 30-min incubation at
37°C of the assay mixture containing PI-3K
from control cells resulted in the formation of
radiolabeled phosphatidylinositol phosphate
(PIP) and phosphatidylinositol bisphosphate
(PIP2). To simplify the analysis, a 10-min
incubation that yielded only PIP was used
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Figure 1. iAsIII and MAsIII inhibit ISGU by adipocytes at concentrations that do not compromise cell viabil-
ity. 3T3-L1 adipocytes were treated with iAsIII (A) or MAsIII (B) for 4 hr. [14C]-2-Deoxyglucose uptake was
assessed in treated and untreated (control) cells after a 10-min activation with insulin. Cell viability was
measured by MTT assay. Each value represents the mean ± SD; n = 3–5 experiments. 
*Statistically signiﬁcant differences (p < 0.05) between treated and control cells. The concentrations of 50 µM iAsIII and
2 µM MAsIII (indicated by arrows) were used in all subsequent experiments.
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Figure 2. ISGU in adipocytes exposed to subtoxic concentrations of iAsIII and MAsIII is independent of cas-
pase-3 activation. (A) Caspase-3 activity was measured in 3T3-L1 adipocytes treated for 4 hr with 50 µM
iAsIII or 2 µM MAsIII and in untreated (control) cells in the presence or absence of 75 µM AC-DEVD-CHO, a
caspase-3 inhibitor. Adipocytes treated with 500 µM H2O2 for 4 hr were used as positive controls. (B) Basal
and insulin-stimulated uptake of [14C]-2-deoxyglucose was measured in adipocytes exposed for 4 hr to
50 µM iAsIII or 2 µM MAsIII in the presence or absence of 75 µM AC-DEVD-CHO. Each value represents the
mean ± SD; n = 3–5 experiments. 
*Statistically signiﬁcant differences (p < 0.05) between treated and untreated (control) cells.
A B *
500 μM
H2O2
*
iAsIII
*
MAsIII
500
400
300
200
100
0
C
a
s
p
a
s
e
-
3
 
a
c
t
i
v
i
t
y
 
(
p
e
r
c
e
n
t
 
o
f
 
c
o
n
t
r
o
l
)
10
8
6
4
2
0
[
1
4
C
]
-
2
-
D
e
o
x
y
g
l
u
c
o
s
e
 
u
p
t
a
k
e
(
D
P
M
/
m
g
 
p
r
o
t
e
i
n
ˆ
1
0
3
–
Control
+
Control
+
iAsIII
+
MAsIII
Insulin
Presence of 75 μM AC-DEVD-CHO
Absence of 75 μM AC-DEVD-CHOthroughout this study. Radiolabeled phospho-
lipids were extracted in chloroform:methanol
(CHCl3:CH3OH) (1:1). The organic phase
was washed with CH3OH:HCl (1:1), evapo-
rated under nitrogen, and the residue was dis-
solved in CHCl3:CH3OH (2:1). The extract
was separated by thin-layer chromatography
(TLC) on glass silica plates pretreated with 1%
potassium oxalate, using an n-propanol:2 N
acetic acid (65:35) solvent system (Augustine
et al. 1991). The distribution of radioactivity
on TLC plates was evaluated, using a com-
puterized Fuji FLA-2000 imaging system
(Fujiﬁlm, Stamford, CT). The following stan-
dards were used to conﬁrm the identity of sepa-
rated phospholipids: L-α-phosphatidylinositol,
L-α-phosphatidylinositol-4-phosphate, L-α-
phosphatidylinositol-4,5-bisphosphate (Avanti
Polar Lipids Inc.). Standards were visualized on
developed TLC plates by treatment with 50%
sulfuric acid at 100°C for 1 hr. 
PKB/Akt assay. We measured PKB/Akt
activity using an Akt1/PKBα Immuno-
precipitation-Kinase Assay Kit (Upstate
Biotechnology), following the manufacturer’s
protocol. PKB/Akt was immunoprecipitated
with an antibody raised against the pleckstrin
homology domain of PKB/Akt. The assay
mixture contained 20 mM morpholine-
propanesulfonic acid (pH 7.2), 25 mM
β-glycerophosphate, 5 mM EGTA, 1 mM
Na3VO4, 1 mM dithiothreitol, 10 mM pro-
tein kinase A (PKA) inhibitor peptide
(Upstate Biotechnology), 19 mM MgCl2,
125 µM ATP, 5 µCi [γ-32P]-ATP, and
Akt/SGK peptide as a substrate. Incubation
was carried out at 30°C for 10 min with con-
tinuous shaking. The radiolabeled peptide was
blotted on P81 phosphocellulose and quanti-
ﬁed by liquid scintillation.
PDK-1 assay. PDK-1 activity was meas-
ured using a PDK-1 Kinase Assay Kit (Upstate
Biotechnology). PDK-1 was immunoprecipi-
tated with an anti-p-PDK-1(Ser241) antibody
(Cell Signaling Technology). The assay mixture
contained 50 mM Tris–HCl (pH 7.5),
0.1 mM EGTA, 0.1 mM EDTA, 1 mM
Tris(2-carboxyethyl) phosphine, 25 µM PKA
peptide inhibitor (Upstate Biotechnology),
1 µM microcystin-LR, 10 mM magnesium
acetate, 15 mM MgCl2, 100 µM ATP and
5 µCi [γ-32P]-ATP. The assay was performed at
30°C in two incubation steps. In the first
30-min step, PDK-1 phosphorylates (activates)
recombinant serum and glucocorticoid-induced
protein kinase-1 (SGK1). In the second 10-min
step, the activated SGK1 phosphorylates a syn-
thetic peptide (RPRAATF) using [γ-32P]-ATP
as a phosphate donor. The radiolabeled pep-
tide is blotted on P81 phosphocellulose and
quantiﬁed by liquid scintillation.
Statistical analysis. All experiments were
replicated to ensure the reproducibility of
results. Representative findings are shown.
Results of the cell viability, glucose uptake,
and protein kinase activity assays were evalu-
ated by analysis of variance with Tukey multi-
ple comparison posttest using a GraphPad
Instat statistical software package (GraphPad
Software, San Diego, CA). Differences among
means with p < 0.05 were considered statisti-
cally signiﬁcant.
Results
Our previous work has shown that trivalent
arsenicals inhibit ISGU by 3T3-L1 adipo-
cytes. However, the possible association
between the inhibition of ISGU and a general
loss of cell functions due to the cytotoxicity of
arsenicals has not been thoroughly examined.
In this study we examined ISGU and cell via-
bility in adipocytes exposed for 4 hr to iAsIII
or MAsIII at a wide range of concentrations.
Consistent with our previous report (Walton
et al. 2004), stimulation of 3T3-L1 adi-
pocytes with insulin increased glucose uptake
by 9- to 11-fold over basal levels (data not
shown). ISGU was signiﬁcantly inhibited by
concentrations as low as 5 µM iAsIII and
0.5 µM MAsIII (Figure 1A, B). In contrast,
cell viability decreased only when concentra-
tions of iAsIII and MAsIII exceeded 1 mM and
5 µM, respectively. Gross abnormalities in
adipocyte morphology were absent at all con-
centrations tested, although minor cell
detachment did occur at higher concentra-
tions (≥ 200 µM iAsIII and ≥ 10 µM MAsIII).
The estimated IC50 (concentration that
results in the inhibition of ISGU by 50%)
values for the inhibition of ISGU were 25 µM
for iAsIII and 4 µM for MAsIII. In compari-
son, the LC50 (concentration that results in a
decrease of cell viability by 50%) values char-
acterizing the cytotoxic effects were 11 mM
for iAsIII and 15 µM for MAsIII. Thus, the
inhibition of ISGU by iAsIII and MAsIII at or
below IC50 values was not due to impaired
adipocyte viability. However, both iAsIII and
MAsIII can induce cell apoptosis (Lau et al.
2004; McCollum et al. 2005; Namgung and
Xia 2001). At early stages, apoptotic processes
may affect cell functions without having
Inhibition of insulin signal by inorganic and methyl arsenic
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Figure 3. Four-hour exposures to subtoxic concentrations of iAsIII or MAsIII do not increase DNA fragmen-
tation in cultured adipocytes. DNA fragmentation was measured by TUNEL in 3T3-L1 adipocytes treated
with 50 µM iAsIII or 2 µM MAsIII for 4, 24, 48, and 72 hr. Untreated adipocytes were used as controls. Color
images show green ﬂuorescein signal of fragmented DNA in apoptotic cells. Gray-scale images illustrate
the corresponding cell morphology. Representative fields of two independent experiments are shown.
Bars = 40 µm. 
4 hr
24 hr
48 hr
72 hr
Control
iAsIII MAsIIIimmediate effects on cell viability. We exam-
ined apoptotic markers in adipocytes exposed
for 4 hr to 50 µM iAsIII and 2 µM MAsIII, the
concentrations that effectively inhibit ISGU,
but are far below the minimal cytotoxic con-
centrations. Under these exposure conditions,
both iAsIII and MAsIII signiﬁcantly increased
the activity of caspase-3, an early marker of
apoptosis (Figure 2A). Adipocytes treated with
500 µM H2O2 were used as positive controls
for this experiment. Pretreatment with 75 µM
Ac-Asp-Glu-Val-Asp-CHO (AC-DEVD-
CHO), a cell-permeable caspase-3 inhibitor,
prevented caspase-3 activation by both arseni-
cals and by hydrogen peroxide. However, pre-
treatment with AC-DEVD-CHO did not
prevent the decrease in ISGU in cells treated
with either iAsIII or MAsIII (Figure 2B), sug-
gesting that the inhibition of ISGU was inde-
pendent of processes associated with early
stages of apoptosis. TUNEL was used to
determine the degree of DNA fragmentation
in adipocytes exposed to 50 µM iAsIII or
2 µM MAsIII (Figure 3). Adipocyte nuclei
were stained with DAPI to determine the
total number of cells (data not shown). The
average apoptotic index (percentage of
TUNEL-positive cells) was about 16% for
control adipocytes and did not change after a
4-hr exposure to either iAsIII or MAsIII.
However, the apoptotic index increased con-
siderably after longer exposure times, reaching
an average of 32% for iAsIII and 39% for
MAsIII after 24 hr and more than 90% after
72-hr exposure to either arsenical. These data
suggest that 4-hr exposures to 50 µM iAsIII or
2 µM MAsIII did not compromise cell viabil-
ity or integrity. In addition, neither 50 µM
iAsIII nor 2 µM MAsIII induced p38 MAPK
phosphorylation during the 4-hr exposure
(data not shown). Therefore, the inhibition of
ISGU is not associated with stress and is
likely due to speciﬁc effects of these arsenicals
on mediators of insulin signaling or on the
cellular components involved in glucose
transport. Based on these results, 4-hr expo-
sures to 50 µM iAsIII and 2 µM MAsIII were
used in further experiments to examine the
effects of iAsIII or MAsIII on components of
the insulin-activated signal transduction path-
way in 3T3-L1 adipocytes. 
The effects of iAsIII or MAsIII on media-
tors of insulin signaling would ultimately
depend on the intracellular concentrations
and metabolic conversion of these arsenicals.
We examined the distribution of As species in
adipocytes after a 4-hr exposure to iAsIII or
MAsIII, using HG-AAS. Cells exposed to
50 µM iAsIII retained about 3 times more As
than cells exposed to 2 µM MAsIII (Figure 4).
Retained As represented 2.5 and 16% of the
total As in cultures exposed to iAsIII or
MAsIII, respectively. Only iAs and MAs
species were detected in adipocyte cultures
exposed to iAsIII and MAsIII, respectively,
indicating that no methylation conversion
took place during the 4-hr exposures. These
findings are consistent with previous reports
that found adipocytes to be inefﬁcient methy-
lators of iAs (Walton et al. 2004).
The translocation of GLUT4 from the
perinuclear compartment to the plasma mem-
brane is a prerequisite for glucose uptake in
adipocytes stimulated with insulin. We used
immunofluorescent staining in this study to
examine the association of GLUT4 with the
plasma membranes of insulin-stimulated
3T3-L1 adipocytes treated with 50 µM iAsIII
or 2 µM MAsIII for 4 hr and from control
(untreated) cells that were or were not stimu-
lated with insulin (Figure 5). Stimulation
with insulin dramatically increased the
GLUT4-speciﬁc ﬂuorescent signal in plasma
membrane lawns of control cells. GLUT4 sig-
nals in plasma membrane lawns isolated from
insulin-stimulated cells treated with either
iAsIII or MAsIII were noticeably weaker com-
pared with control insulin-stimulated cells,
suggesting that both arsenicals interfered with
the translocation of GLUT4 in response to
insulin stimulation. 
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Figure 4. Retention of As species in 3T3-L1
adipocytes exposed to iAsIII or MAsIII. As species
retained in 3T3-L1 adipocytes exposed for 4 hr to
50 µM iAsIII or 2 µM MAsIII were analyzed by
HG-AAS. Note: The HG-AAS technique used in this
study cannot distinguish between AsIII and AsV
species. Each value represents the mean ± SD; 
n = 3 experiments.
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Figure 5. Exposures to subtoxic concentrations of iAsIII or MAsIII inhibit GLUT4 association with the plasma
membrane of insulin-activated adipocytes. Immunofluorescent images of GLUT4 in plasma membrane
lawns isolated from control (untreated) 3T3-L1 adipocytes before (A) and after activation (B) with insulin
and from insulin-activated adipocytes treated for 4 hr with 50 µM iAsIII (C) or 2 µM MAsIII (D). Adipocytes
were fixed and sonicated to prepare plasma membrane lawns. GLUT4 was labeled with an anti-GLUT4
antibody and visualized with a ﬂuorescent secondary antibody. Representative ﬁelds of two independent
experiments are shown. Bars = 10 µm.The impaired ISGU in adipocytes exposed
to trivalent arsenicals has previously been
linked to the inhibition of components of the
insulin signal transduction pathway located
downstream of IRS1/2, but upstream of
PKB/Akt (Walton et al. 2004). PI-3K is
located downstream of IRS. The binding of
p-IRS to the regulatory (p85) subunit of
PI-3K in response to insulin stimulates the
PI-3K–catalyzed production of PIP3 from
PIP2. In this study, the association of p-IRS
with PI-3K was examined in insulin-stimu-
lated adipocytes exposed for 4 hr to 50 µM
iAsIII or 2 µM MAsIII. Neither iAsIII nor
MAsIII affected the amount of PI-3K (p85),
immunoprecipitated with an anti-phospho-
tyrosine (PY20) antibody, which reacts with
phosphorylated tyrosine residues of IRS in the
insulin-activated PI-3K complex (Figure 6A).
PI-3K activity was measured in adipocytes
exposed for 4 hr to 50 or 100 µM iAsIII or to
2 or 5 µM MAsIII. Exposures to iAsIII had no
effect on PI-3K activity. A relatively small
decrease in PI-3K activity was detected in cells
exposed to 2 µM MAsIII; however, no changes
were found in cells exposed to 5 µM MAsIII
(data not shown). Effects of MAsIII on PI-3K
activity were further analyzed in an in vitro
assay mixture containing PI-3K immunopre-
cipitated from control insulin-stimulated
adipocytes. Addition of MAsIII into this mix-
ture at concentrations up to 50 µM did not
inhibit PI-3K activity (data not shown).
PTEN, a PIP3 phosphatase, is involved in the
regulation of PIP3 levels in adipocytes. PTEN
activity is regulated by a casein kinase 2–cat-
alyzed phosphorylation on its C-terminal non-
catalytic regulatory domain, which includes
Ser380 (Torres and Pulido 2001). Neither
50 µM iAsIII nor 2 µM MAsIII altered the lev-
els of total PTEN or pPTEN (Ser380)
(Figure 6A). No changes in the of ratio of
phosphorylated pPTEN (Ser380) to total
PTEN were found in insulin-stimulated
adipocytes exposed to either iAsIII or MAsIII
(Figure 6B).
Phosphorylation on Ser241 is required for
optimal activity of PDK-1, a downstream
effector of PI-3K (Casamayor et al. 1999).
Figure 7A shows that exposures to 50 µM
iAsIII or 2 µM MAsIII had no significant
effects on the level of Ser241-phosphorylated
PDK-1 in insulin-stimulated adipocytes.
However, PDK-1 activity was significantly
lower in cells exposed to either iAsIII or
MAsIII, 47% and 57% of that in control cells,
respectively (Figure 7B). 
In the insulin-activated signal transduction
pathway, PKB/Akt is the downstream effector
of PDK-1. The activation of PKB/Akt in
response to insulin stimulation includes the
phosphorylation of Ser473 and Thr308
residues (Toker and Newton 2000). Our pre-
vious work demonstrated that exposures to
iAsIII or MAsIII inhibit PKB/Akt phosphoryla-
tion on Ser473 (Walton et al. 2004), which is
thought to be catalyzed by a putative
Ser-kinase, PDK-2 (Toker and Newton 2000).
PDK-1 is responsible for Thr308 phosphoryla-
tion, which is required for maximal PKB/Akt
activity (Scheid et al. 2002). Immunoblot
analysis carried out in this study showed that
4-hr exposures to 50 µM iAsIII or 2 µM MAsIII
inhibited the insulin-dependent phosphoryla-
tion of PKB/Akt on both Ser473 and Thr308
residues (Figure 8A). PKB/Akt activity in
Inhibition of insulin signal by inorganic and methyl arsenic
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Figure 6. Exposures to subtoxic concentrations of iAsIII or MAsIII do not affect insulin signal mediators that
regulate PIP3 levels in insulin-activated adipocytes. (A) Immunoblot analyses of the activated PI-3K, total
PTEN, and phosphorylated PTEN (Ser380) in control 3T3-L1 adipocytes before or after activation with
insulin and in insulin-activated adipocytes treated for 4 hr with 50 µM iAsIII or 2 µM MAsIII. Activated PI-3K
was immunoprecipitated from control and exposed cells with an anti-phospho-Tyr (PY20) antibody and
immunoblotted with an antibody against the regulatory (p85) subunit. Representative blots of three inde-
pendent experiments are shown. (B) The ratio of phosphorylated PTEN (Ser380) to total PTEN expressed
as a percent of the ratio found in control adipocytes before activation with insulin. Each value represents
the mean ± SD; n = 3 experiments.
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Figure 7. Exposures to subtoxic concentrations of AsIII or MAsIII do not affect the phosphorylation of
PDK-1 but inhibit PDK-1 activity in adipocytes. (A) Immunoblot analysis of Ser241-phosphorylated PDK-1 in
insulin-activated 3T3-L1 adipocytes treated for 4 hr with 50 µM iAsIII or 2 µM MAsIII and in control
(untreated) insulin-activated adipocytes. Representative blot of three independent experiments is shown.
(B) The kinase activity of PDK-1 immunoprecipitated from insulin-activated control or treated 3T3-L1
adipocytes. Each value represents the mean ± SD; n = 4–5 experiments. 
*Statistically signiﬁcant differences (p < 0.05) between treated and control cells.
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Figure 8. Exposures to subtoxic concentrations of iAsIII or MAsIII inhibit the phosphorylation and PKB/Akt.
(A) Immunoblot analysis of total PKB/Akt and Ser473- or Thr308-phosphorylated PKB/Akt in insulin-acti-
vated 3T3-L1 adipocytes treated for 4 hr with 50 µM iAsIII or 2 µM MAsIII and in insulin-activated control
(untreated) cells. Representative blots of three independent experiments are shown. (B) The activity of
PKB/Akt immunoprecipitated from insulin-activated control and treated adipocytes. Each value represents
the mean ± SD; n = 4–5 experiments. 
*Statistically signiﬁcant differences (p < 0.05) between treated and control cells.
A Control B
Control iAsIII MAsIII
125
100
75
50
25
0
P
K
B
/
A
k
t
 
a
c
t
i
v
i
t
y
(
p
e
r
c
e
n
t
 
o
f
 
c
o
n
t
r
o
l
)
*
*
iAsIII MAsIII
pPKB/Akt
(Ser473)
β-actin
PKB/Akt
pPKB/Akt
(Thr308)insulin-stimulated adipocytes exposed to iAsIII
and MAsIII was 47 and 28% of that in control
insulin-activated cells, respectively (Figure 8B). 
To further evaluate the role of the
PDK-1/PKB/Akt signal transduction step as a
target for trivalent arsenicals in the insulin-
activated signal transduction pathway, we
examined the effects of iAsIII or MAsIII on
ISGU by adipocytes expressing constitutively
active myr-PKB/Akt. Adipocytes expressing
an inactive A2myr-PKB/Akt mutant or
empty expression vector were used as negative
controls. Consistent with the constitutive
activation of PKB/Akt, glucose uptake by
adipocytes expressing myr-PKB/Akt was ele-
vated even in the absence of insulin stimula-
tion (Figure 9). Four-hour exposures to
50 µM iAsIII or 2 µM MAsIII had no effect on
ISGU by myr-PKB/Akt expressing cells. In
contrast, both arsenicals inhibited ISGU in
cells expressing the inactive A2myr-PKB/Akt
mutant or the empty expression vector. 
Discussion
Previous studies have shown that AsIII-contain-
ing species may affect glucose uptake by cul-
tured cells or dissected tissues by two
independent mechanisms that strictly depend
on the concentration of AsIII. Highly-toxic
concentrations of AsIII stimulate glucose
uptake in the absence of insulin (Bazuine et al.
2003, 2004; Brazy et al. 1980; McDowell et al.
1997; Pasternak et al. 1991; Short 1965;
Sviderskaya et al. 1996; Widnell et al. 1990)
through a mechanism that involves activation
of p38 MAPK-mediated stress signaling and
PI-3K-dependent phosphorylation of PKB/Akt
(Souza et al. 2001). In our experiments, expo-
sure of 3T3-L1 adipocytes to 50 µM iAsIII and
2 µM MAsIII for 4 hr did not activate p38
MAPK, thus providing further evidence of the
subtoxic nature of our exposure conditions.
Treatments with toxic concentrations of
arsenicals are not comparable to environmental
or occupational exposures to iAs that do not
typically induce acute stress or tissue damage.
In contrast, subtoxic concentrations of AsIII
inhibit ISGU (Henriksen and Holloszy 1990;
Liebl et al. 1992, 1995; Sowell et al. 1988) in a
manner consistent with impaired glucose toler-
ance reported among individuals chronically
exposed to relatively low concentrations of iAs.
We have shown that inhibition of ISGU in
adipocytes exposed to subtoxic concentrations
of trivalent metabolites of iAs, iAsIII, or MAsIII
is associated with the suppression of PKB/Akt
phosphorylation (Walton et al. 2004). Because
neither iAsIII nor MAsIII interfered with insulin
signaling upstream of PI-3K (Walton et al.
2004), the present work focused on the signal
transduction steps immediately preceding
PKB/Akt phosphorylation, speciﬁcally, on the
enzymatic system controlling PIP3 levels in
insulin-activated cells and on PDK-1. 
The formation of PIP3 catalyzed by the
insulin-activated PI-3K-IRS complex is an
essential step in ISGU by adipocytes. PIP3 is
required for PDK-1–catalyzed phosphorylation
of PKB/Akt on Thr308 (Casamayor et al.
1999). PIP3 is thought to interact directly with
the PH-domain of PDK-1 and PKB/Akt, acti-
vating PDK-1 or facilitating Thr308 phospho-
rylation of PKB/Akt. Other studies suggest
that PIP3 promotes the phosphorylation of
PKB/Akt on Ser473 by a putative PDK-2,
thereby priming PKB/Akt for PDK-1–cat-
alyzed phosphorylation of Thr308 (Toker and
Newton 2000). PIP3 concentration in the
membrane region of cells is subjected to strict
regulation involving PI-3K and speciﬁc lipid
phosphatases, including PTEN (Maehama
and Dixon 1998) and SHIP2 (Src homol-
ogy 2-containing inositol 5´-phosphatase 2)
(Wada et al. 2001). Both PTEN, a D-3 lipid
phosphatase, and SHIP2, a D-5 lipid phos-
phatase, are expressed in adipocytes. However,
a recent report suggests that only PTEN is
capable of suppressing insulin signaling in
3T3-L1 adipocytes (Tang et al. 2005). PTEN
is phosphorylated on Ser380 and Thr382/383
by casein kinase 2 (Torres and Pulido 2001).
The phosphorylated PTEN (p-PTEN) is less
susceptible to degradation by the proteosome
but is less active. Inhibition of Ser380 phos-
phorylation increases PTEN activity, but
destabilizes the enzyme (Georgescu et al. 1999;
Tolkacheva and Chan 2000). Factors that
interfere with PI-3K activation in response to
insulin or inhibit PTEN phosphorylation may
decrease PIP3 levels in adipocytes and,
ultimately, prevent PDK-1/2–catalyzed phos-
phorylation of PKB/Akt. 
In this study, iAsIII and MAsIII inhibited
PDK-1/2 catalyzed phosphorylation of
PKB/Akt on Thr308 and Ser473 but had lit-
tle or no effect on PI-3K activity or PTEN
phosphorylation. In addition, neither iAsIII
nor MAsIII affected PDK-1(Ser241) phospho-
rylation, which is essential for PDK-1 activity.
These results suggest that iAsIII and MAsIII
inhibit PDK-1 activity through direct interac-
tions with the enzyme. Sulfhydryl groups of
vicinal or closely spaced cysteines are typical
high-afﬁnity targets for trivalent arsenicals in
protein structures (Altamirano et al. 1989;
Carlson et al. 1978; Chakraborti et al. 1992;
Delnomdedieu et al. 1993; Li et al. 2001;
Lopez et al. 1990). Two such closely spaced
cysteines (Cys21 and Cys23) are present in
the N-terminus of both mouse and human
PDK-1 (Alessi et al. 1997; Dong et al. 1999).
Thus, it is plausible that binding of iAsIII and
MAsIII to Cys21 and Cys23 is the proximate
cause of PDK-1 inhibition by these arsenicals.
However, unlike MAsIII, which can form a
Paul et al.
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Figure 9. Constitutive activation of protein kinase B
(PKB/Akt) prevents the inhibition of insulin-stimu-
lated glucose uptake in adipocytes treated with
subtoxic concentrations of iAsIII or MAsIII. Basal
and insulin-stimulated [14C]-2-deoxyglucose uptake
by 3T3-L1 adipocytes treated for 4 hr with 50 µM
iAsIII or 2 µM MAsIII and by untreated adipocytes
expressing a constitutively active myr-PKB/Akt)
(black bar, an inactive PKB/Akt mutant (A2myr-
PKB/Akt) (blue bar), or an empty expression vector
(white bar). Each value represents the mean ± SD;
n = 4–5 experiments. 
*Statistically significant differences (p < 0.05) between
treated and control cells. 
10
8
6
4
2
0
[
1
4
C
]
-
2
-
D
e
o
x
y
g
l
u
c
o
s
e
 
u
p
t
a
k
e
(
D
P
M
/
m
g
 
p
r
o
t
e
i
n
)
ˆ
1
0
3
–
Control
+
Control
*
+
iAsIII
* *
+
MAsIII
*
Insulin
Figure 10. The molecular mechanism underlying the inhibition of insulin-stimulated glucose uptake by
adipocytes exposed to iAsIII or MAsIII. The inhibition of PDK-1 and putative PDK-2 activities by iAsIII and
MAsIII results in suppression of the downstream signaling steps, including PKB/Akt phosphorylation and
GLUT4 translocation to the plasma membrane.stable cyclic structure with two thiols, iAsIII
may require three coordination bonds to form
a stable enzyme-inhibitor complex. A lower
afﬁnity for binding to Cys21 and Cys23 may
explain why iAsIII is a weaker inhibitor of
PDK-1 than MAsIII. In addition, the differ-
ence in potencies of iAsIII and MAsIII to
inhibit PDK-1 activity and ISGU may be in
part due to differences in the uptake and/or
retention of these arsenicals by adipocytes.
Our data suggest that MAsIII was retained by
3T3-L1 adipocytes more efficiently than
iAsIII. These ﬁndings are consistent with the
results of previous studies in other cell types
(Dopp et al. 2004; Drobna et al. 2005).
Importantly, our data show that the expres-
sion of constitutively active myrPKB/Akt pre-
vents the inhibition of ISGU by either iAsIII
or MAsIII. These data provide further evi-
dence that the inhibition of ISGU by 3T3-L1
adipocytes exposed to iAsIII and MAsIII is due
to the inhibition of the PDK-1–catalyzed
activation of PKB/Akt and that neither iAsIII
nor MAsIII disrupts signal transduction steps
downstream from PDK-1/PKB/Akt, or events
associated with GLUT4 translocation to the
plasma membrane. 
In summary, subtoxic concentrations of
iAsIII and MAsIII inhibit ISGU by 3T3-L1
adipocytes through a mechanism that involves
the inhibition of PDK-1 activity and of
PDK-1/2–catalyzed phosphorylation of
PKB/Akt (Figure 10). The inhibition of
ISGU by iAsIII and MAsIII, trivalent metabo-
lites of iAs, is consistent with impaired glu-
cose tolerance reported in individuals
chronically exposed to iAs from the environ-
ment. In addition, the concentrations of iAsIII
and MAsIII that inhibit ISGU by cultured
adipocytes (as low as 5 and 0.5 µM, respec-
tively) appear to be compatible with this type
of exposure. Thus, taken together, this work
provides a mechanistic basis for the diabeto-
genic effects of chronic environmental and
occupational exposures to iAs.
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